Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ixabepilone + bevacizumab
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Ixabepilone + bevacizumab is a combination regimen used primarily in the treatment of platinum-resistant or platinum-refractory ovarian, fallopian tube, and primary peritoneal cancers. Ixabepilone is a semi-synthetic epothilone B analogue that acts as a microtubule-stabilizing agent by binding to β-tubulin subunits, suppressing their dynamic instability, blocking mitosis, and inducing cell death. It retains activity in taxane-resistant tumors due to its distinct binding mode and resistance to P-glycoprotein-mediated efflux. Bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor (VEGF), inhibiting angiogenesis required for tumor growth. The combination has demonstrated improved progression-free survival (PFS) and overall survival (OS) compared with ixabepilone alone in clinical trials for heavily pretreated patients with platinum-resistant ovarian cancer[1][3][4][5][8]. Ixabepilone was developed by Bristol Myers Squibb; bevacizumab was developed by Genentech/Roche.
- Other names
- ixabepilone + bevacizumab
02
Targets
VEGFA (Vascular endothelial growth factor A)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on ixabepilone + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ixabepilone + bevacizumab.